ANTXR1 and prostate cancer: TEM8/ANTXR1 upregulation has been described in a variety of solid tumors types including triple negative breast cancer (Xu et al., 2021), prostate cancer (Li et al., 2021a), gastric cancer (Li et al., 2021b; Sun et al., 2021), pancreatic cancer (Alcalá et al., 2019), angiosarcoma (Kusaba et al., 2021), colon cancer (Ł et al., 2021), and NSCLC (Gong et al., 2021).